Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Titan Pharma (TTNP)

Titan Pharma (TTNP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 22,998
  • Shares Outstanding, K 6,552
  • Annual Sales, $ 3,610 K
  • Annual Income, $ -16,460 K
  • 60-Month Beta 1.05
  • Price/Sales 6.82
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade TTNP with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -2.40
  • Growth Rate Est. (year over year) +41,725.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.82 +29.08%
on 11/06/20
8.85 -58.87%
on 11/20/20
+0.48 (+15.01%)
since 11/03/20
3-Month
2.82 +29.08%
on 11/06/20
8.85 -58.87%
on 11/20/20
-2.38 (-39.51%)
since 09/03/20
52-Week
2.82 +29.08%
on 11/06/20
16.35 -77.74%
on 03/03/20
-1.79 (-32.97%)
since 12/03/19

Most Recent Stories

More News
Thinking about buying stock in Titan Pharmaceuticals, Moderna, Moleculin Biotech, Corbus Pharmaceuticals, or Altimmune?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TTNP, MRNA, MBRX, CRBP, and ALT.

ALT : 12.83 (+8.27%)
CRBP : 1.3300 (unch)
MRNA : 157.26 (+9.97%)
MBRX : 0.8401 (-0.15%)
TTNP : 3.64 (+3.70%)
Titan Pharmaceuticals Announces Reverse Stock Split

, /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that its Board of Directors has approved a 1-for-30 reverse stock split of the Company's common...

TTNP : 3.64 (+3.70%)
Thinking about buying stock in FuelCell Energy, Titan Pharmaceuticals, Vale SA, AMC Entertainment, or American Eagle Outfitters?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for FCEL, TTNP, VALE, AMC, and AEO.

AC : 35.58 (-3.45%)
FCEL : 7.38 (+1.93%)
TTNP : 3.64 (+3.70%)
AEO : 18.89 (+2.94%)
AMC : 3.63 (-15.97%)
VALE : 15.34 (+0.07%)
Thinking about buying stock in Nio, Titan Pharmaceuticals, Zomedica Corp, Gevo Inc, or Transocean?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NIO, TTNP, ZOM, GEVO, and RIG.

ZOM : 0.1755 (-7.09%)
GEVO : 1.7900 (-4.79%)
TTNP : 3.64 (+3.70%)
NIO : 45.35 (-5.48%)
RIG : 2.03 (-2.87%)
Opioid Use Disorder Market to Soar at 10.8% CAGR and Hit USD 4.50 Billion by 2026; Increasing Research in Opioids by Pharmaceuticals to Aid Market Expansion: Fortune Business Insights(TM)

The global Opioid Use Disorder Market size is projected to reach USD 4.50 billion by 2026, exhibiting a CAGR of 10.8% during the forecast period. Increasing addiction to opioids across the globe will be...

ALKS : 19.00 (+0.96%)
BDSI : 3.84 (-0.26%)
HKMPF : 35.0388 (+0.50%)
IZQVF : 1.3800 (unch)
PFE : 40.09 (-1.74%)
TTNP : 3.64 (+3.70%)
Thinking about buying stock in Titan Pharmaceuticals, Electrameccanica Vehicles, FuelCell Energy, Riot Blockchain, or Coty?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TTNP, SOLO, FCEL, RIOT, and COTY.

FCEL : 7.38 (+1.93%)
SOLO : 6.98 (+0.29%)
RIOT : 9.66 (+13.51%)
TTNP : 3.64 (+3.70%)
COTY : 7.53 (+1.89%)
Thinking about buying stock in Sundial Growers, HL Acquisitions, Intel Corp, Titan Pharmaceuticals, or Nokia?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SNDL, HCCH, INTC, TTNP, and NOK.

HCCH : 18.77 (+8.18%)
INTC : 50.99 (+2.18%)
SNDL : 0.7727 (-4.37%)
TTNP : 3.64 (+3.70%)
NOK : 4.02 (-0.99%)
Thinking about buying stock in Titan Pharmaceuticals, Norwegian Cruise Line, Delta Air Lines, Zomedica, or Sundial Growers?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TTNP, NCLH, DAL, ZOM, and SNDL.

ZOM : 0.1755 (-7.09%)
SNDL : 0.7727 (-4.37%)
TTNP : 3.64 (+3.70%)
DAL : 42.95 (+4.58%)
NCLH : 25.42 (+8.63%)
Titan Pharmaceuticals: 3Q Earnings Snapshot

SAN FRANCISCO (AP) _ Titan Pharmaceuticals Inc. (TTNP) on Monday reported a loss of $4.9 million in its third quarter.

TTNP : 3.64 (+3.70%)
Titan Pharmaceuticals Reports Third Quarter 2020 Financial Results

, /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today reported financial results for the third quarter ended and provided an update on its business.

TTNP : 3.64 (+3.70%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Titan Pharmaceuticals, Inc. is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical...

See More

Key Turning Points

2nd Resistance Point 3.93
1st Resistance Point 3.79
Last Price 3.64
1st Support Level 3.50
2nd Support Level 3.35

See More

52-Week High 16.35
Fibonacci 61.8% 11.18
Fibonacci 50% 9.59
Fibonacci 38.2% 7.99
Last Price 3.64
52-Week Low 2.82

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar